josh hardman

The Psychedelic Practitioner: Issue 1 - Psychedelic Alpha Welcome to the inaugural issue of The Psychedelic Practitioner, a new publication for the evolving practice of psychedelic care.

Today, we launch The Psychedelic Practitioner by Psychedelic Alpha

It’s designed specifically for therapists, clinicians, facilitators, and other professionals working with—or preparing to work with—psychedelic therapies and related treatments.

Read now: psychedelicalpha.com/news/the-psy...

Q3 2025 Psychedelic Investor Survey Results

Today, we share topline results from the latest in our series of psychedelics investor surveys.

Explore: psychedelicalpha.com/news/psyched...

The Psychedelic News Feed: Sept 29 - Oct 5, 2025 - Psychedelic Alpha Your one-stop digest for the latest coverage of psychedelics business, policy, research and beyond, for the week commencing September 29, 2025.

The Psychedelic News Feed: Sept 29 - Oct 5, 2025

psychedelicalpha.com/news/the-psy...

Breakthrough Data, Black Box Sessions: A Closer Look at MindMed’s Phase 2b LSD for GAD Study - Psychedelic Alpha MindMed’s Phase 2b LSD (MM120) for generalised anxiety disorder (GAD) study, published in JAMA earlier this month, shows promising efficacy and a favourable safety profile. Here…

Breakthrough Data, Black Box Sessions: A Closer Look at MindMed’s Phase 2b LSD for GAD Study

We speak to researchers and take a deeper dive into the published study, with a focus on dose-response, safety, and MindMed's eschewing of psychotherapy.

psychedelicalpha.com/news/breakth...

UK Royal College of Psychiatrists Weighs In: Promise in Psychedelics, But Hype Mustn’t Outpace Evidence - Psychedelic Alpha This morning, the UK’s Royal College of Psychiatrists published a Position Statement on psychedelics and related substances for medical use. Here, we briefly unpack the statement, as well as related…

UK Royal College of Psychiatrists Weighs In: Promise in Psychedelics, But Hype Mustn’t Outpace Evidence

This morning, the UK's professional body for psychiatrists published a Position Statement and Guidance Booklet on the use of psychedelics.

psychedelicalpha.com/news/uk-roya...

Q3’25 Psychedelic Drug Development Pipeline: Bullseye Charts - Psychedelic Alpha We present the psychedelic drug development pipeline in two ‘bullseye chart’ formats, as of Q3’2025.

🎯 Our signature Bullseye chart has just been refreshed, mapping the global pipeline of psychedelic drug candidates, from discovery through to (potential) approval.

Explore the latest Bullseye Charts + the full live Tracker now: psychedelicalpha.com/news/q325-ps...

‘No Prejudice, No Hype’: Florence Butlen-Ducuing on Europe’s Psychedelic Renaissance - Psychedelic Alpha From a long stint at the European Medicines Agency’s (EMA) Office of Therapies for Neurological and Psychiatric Disorders to her present-day practice as a clinical psychiatrist at leading cancer…

From the EMA to Gustave Roussy, Dr. Florence Butlen-Ducuing has witnessed Europe’s psychedelic renaissance first-hand.

I sat down with her to discuss.

psychedelicalpha.com/news/no-prej...

Unpacking FDA’s MDMA Rejection Letter and the Road Ahead for Lykos - Psychedelic Alpha Last Thursday, FDA published the complete response letter (CRL) it sent to Lykos Therapeutics last year, when it rejected its MDMA for PTSD new drug application. Here, we take a closer look at the…

On Thursday, we broke the news that FDA had published the Complete Response Letter (CRL) it sent to Lykos Therapeutics 13 months ago today, when it rejected its MDMA for PTSD new drug application.

Today, we take a much closer (~5,000 word) look...

More: psychedelicalpha.com/news/unpacki...

BREAKING: FDA Publishes Lykos Therapeutics’ MDMA Complete Response Letter (CRL) - Psychedelic Alpha FDA has published its complete response letter (CRL) to Lykos Therapeutics, citing durability, safety, and bias concerns in rejecting MDMA therapy for PTSD. Here, we very briefly unpack the letter.

BREAKING: FDA Publishes Lykos Therapeutics’ MDMA Complete Response Letter (CRL)

psychedelicalpha.com/news/breakin...

Wow, that’s amazing! Send me an email/DM to sort a coupon out 🏷️

Pα+ Psychedelic Bulletin #207: Lykos Rebrands to Resilient; Pharma Pushes Back on Norway’s Ketamine Reimbursement Decision; AbbVie-Gilgamesh Deal Viewed as Validation - Psychedelic Alpha Lykos Therapeutics Rebrands to Resilient Pharmaceuticals • Pharma Pushes Back on Norway’s Off-Label Ketamine Decision • AbbVie–Gilgamesh Deal Viewed as Validation for Short-Acting Psychedelics •

Pα+ Psychedelic Bulletin #207

- Lykos Rebrands to Resilient

- Pharma Pushes Back on Norway’s Ketamine Reimbursement Decision

- AbbVie-Gilgamesh Deal Viewed as Validation

- Psilocybin Rescheduling Petition Heads to HHS

- Much, much more...

psychedelicalpha.com/news/p%ce%b1...

Norway Approves Public Funding for Generic Ketamine in Treatment-Resistant Depression - Psychedelic Alpha This morning, in a world-first move, Norwegian regulators approved national reimbursement for the off-label use of generic ketamine in treatment-resistant depression. Here, we break the news…

Another scoop today.

One of the world's best healthcare systems has decided to reimburse generic ketamine for treatment-resistant depression.

Note that J&J's Spravato (esketamine nasal spray) is not reimbursed for TRD in the Nordic country.

Big news...

psychedelicalpha.com/news/norway-...

July 2025 Psychedelic Patent Update - Psychedelic Alpha Explore our interactive database of psychedelic patent activity in July 2025 via our Pα+ interface. Plus, we look at how a new patent family provides a look at Rivo Bio.

July 2025 Psychedelic Patent Update

Explore our interactive database of psychedelic patent activity in July 2025 via our Pα+ interface. Plus, we look at how a new patent family provides a look at Rivo Bio.

psychedelicalpha.com/news/july-20...

Discover Psychedelic Alpha like never before by using our new AI search tool, trained exclusively on in-house content and data.

Use any search bar on our website to get started, or visit our dedicated webpage: psychedelicalpha.com/ai

Reunion Neuroscience Posts Strong Phase 2 Results for RE104 in Postpartum Depression - Psychedelic Alpha This morning, Reunion Neuroscience posted positive topline results from its Phase 2 study of RE104, its 4-OH-DiPT prodrug, in postpartum depression (PPD). We spoke with Reunion leadership to dig deepe...

BREAKING: Reunion Neuroscience Posts Strong Phase 2 Results for RE104 in Postpartum Depression

Read our Deep Dive coverage, including a discussion with company management, now.

psychedelicalpha.com/news/reunion...

Fantastic discussion between two excellent psychedelic scientists, spanning the generations of research progress! It really should say Huxley to Hefter to Jaster! Well done @jasteralaina.bsky.social!

I got to interview one of my academic heroes 😎🧠🍄

Read the interesting conversation on Psychedelic Alpha!

Heffter Research Institute co-founder Dr. Mark Geyer spoke with Dr. Alaina Jaster for our latest interview.

Among the topics they discussed were so-called non-hallucinogenic psychedelics.

Read more: psychedelicalpha.com/news/from-hu...

From Huxley to Heffter: Mark Geyer Reflects on a Life in Psychedelic Research - Psychedelic Alpha Dr. Alaina Jaster speaks with Dr. Mark Geyer in a discussion that traces his path to psychedelics research, the field’s scientific and cultural shifts, and the role of the Heffter Research Institute.

From Huxley to Heffter: Mark Geyer Reflects on a Life in Psychedelic Research

psychedelicalpha.com/news/from-hu...

Pα+ Psychedelic Bulletin #206: Q2’25 Psychedelic Lobbying; Tabernanthalog’s Neuroplasticity Pathway; UK Moves to Ease Schedule I Research Restrictions - Psychedelic Alpha Q2’25 Psychedelic Lobbying Update • Tabernanthalog Spurs Neuroplasticity via Alternative Pathway, Davis and Delix Researchers Find • UK Moves Toward Easing Schedule I Research Restrictions But Keeps…

Bulletin 206:

- Q2’25 Psychedelic Lobbying Update

- Tabernanthalog Spurs Neuroplasticity via Alternative Pathway, Davis and Delix Researchers Find

- UK Moves Toward Easing Schedule I Research Restrictions But Keeps Industry at Arm’s Length

- and more:

psychedelicalpha.com/news/p%ce%b1...

At-Home Ketamine “Completely Irresponsible”, Says UK Expert

“In the psychedelic world, we are very aware that context is important,” Professor Celia Morgan said, referring to set and setting, as well as the social matrix surrounding the drug user.

psychedelicalpha.com/news/therapy...

Therapy or Threat? UK Expert Warns of Rising Ketamine Addiction as Phase III Alcoholism Trial Launches - Psychedelic Alpha Psychedelic Alpha’s Charles Bliss speaks with Professor Celia Morgan, a leading ketamine researcher, about the promise of ketamine-assisted therapy for alcohol use disorder…

Therapy or Threat? UK Expert Warns of Rising Ketamine Addiction as Phase III Alcoholism Trial Launches

Charles Bliss speaks with Professor Celia Morgan about ketamine's promise and pitfalls.

psychedelicalpha.com/news/therapy...

Last Week in Psychedelics.

Bookmark the live Feed: psychedelicalpha.com/live

Pα+ Psychedelic Bulletin #205: AbbVie Eyes Gilgamesh; Psychedelics Use Increases in U.S.; FDA Moves to Ban Kraton Compound 7-OH; What Is Sinema Selling? - Psychedelic Alpha AbbVie Eyes Billion-Dollar Gilgamesh Acquisition • What Is Kyrsten Sinema Selling? • Compass ‘Encouraged’ by Germany’s Psilocybin Compassionate Use Program • Psychedelics Industry’s Input on EMA’s Dra...

Pα+ Psychedelic Bulletin #205:

- AbbVie Eyes Gilgamesh

- Psychedelics Use Increases in U.S.

- FDA Moves to Ban Kraton Compound 7-OH

- What Is Sinema Selling?

- and much, much more (5,000+ words!)

psychedelicalpha.com/news/p%ce%b1...

Germany joins Switzerland in allowing certain European patients to access psilocybin when they have exhausted other options.

The imprimatur of Swiss engineering & German efficiency and process-focus could add to psychedelic medicine’s legitimacy.

More: psychedelicalpha.com/news/germany...

Germany Establishes EU’s First Psilocybin Compassionate Access Program - Psychedelic Alpha Germany has become the first EU country to allow legal access to psilocybin under a compassionate use program for treatment-resistant depression. Unlike other countries’ pre-approval pathways, Germany...

BREAKING: German regulators have green-lit the EU's first psilocybin compassionate access program.

Unlike other countries’ pre-approval pathways, Germany’s does not require case-by-case regulatory approval and may see insurers cover costs.

Details: psychedelicalpha.com/news/germany...

Dispatch: The Neurobiology of Psychedelics Gordon Research Conference — Circuitry, Consciousness, and Clinical Horizons (Part 2) - Psychedelic Alpha In this second Dispatch from the inaugural Neurobiology of Psychedelics Gordon Research Conference, Dr. Alaina Jaster recaps Days 2 through 4, highlighting cutting-edge research on neuroplasticity…

Dispatch: The Neurobiology of Psychedelics Gordon Research Conference — Circuitry, Consciousness, and Clinical Horizons (Part 2)

Reporting by @jasteralaina.bsky.social.

The entire Dispatch is now free to read.

psychedelicalpha.com/news/dispatc...

Pα+ Psychedelic Bulletin #204: FDA Keeps GH Research’s 5-MeO-DMT on Ice; Makary’s Priority Voucher Pilot Launches, Mentions Innovative PTSD Treatments; HALT Fentanyl Act Could Streamline Schedule I Re... FDA Keeps GH Research’s 5-MeO-DMT on Ice as atai and Beckley Surge Ahead • Makary’s Priority Voucher Program Launches, Cites Novel PTSD Treatment as Example • HALT Fentanyl Act Signed by Trump, Could ...

Pα+ Psychedelic Bulletin #204

📍 FDA Keeps GH Research’s 5-MeO-DMT on Ice

📍 Makary’s Priority Voucher Pilot Launches, Mentions Innovative PTSD Treatments

📍 HALT Fentanyl Act Could Streamline Schedule I Research

📍 and more...

psychedelicalpha.com/news/p%ce%b1...

Q3 2025: Psychedelic Investor Survey

If you have invested in, or are considering investing in, a psychedelics-related company, please complete our latest Psychedelic Investor Survey.

docs.google.com/forms/d/1T_r...

Pα+ Psychedelic Bulletin #203: Norway Considers Funding Off-Label Ketamine for TRD; Longevity Crowd Hypes Psilocybin Study; Will State-Legal Psychedelics Eat Psychedelic Pharma’s Lunch? - Psychedelic ... Norway’s Health System Considers Funding Off-Label Ketamine for Treatment-Resistant Depression • Spravato’s Monotherapy Success Puts Pressure on Psychedelics Developers • Longevity Crowd Hypes Psilocy...

Pα+ Psychedelic Bulletin #203:

🔑 Above the Paywall: Norway’s Health System Considers Funding Off-Label Ketamine for Treatment-Resistant Depression

🐁 Longevity Crowd Hypes Psilocybin Study But Researchers Urge Caution

and more...

psychedelicalpha.com/news/p%ce%b1...